The Relationship Between Social Anxiety and Anxious Thinking Styles
1 other identifier
interventional
85
1 country
1
Brief Summary
This study aims to investigate whether reductions in negative interpretation biases, induced via an experimental manipulation (Cognitive Bias Modification for Interpretation; CBM-I), lead to reductions in symptoms of social anxiety amongst individuals experiencing high levels of social anxiety. The study further aims to investigate the relationship between multifaceted measures of interpretation bias, psychopathological symptoms, neurophysiological indices, behavioral indices of stress reactivity, and SAD symptoms. To achieve these aims a sample of individuals experiencing high levels of social anxiety will be recruited. After completing multi-faceted measures of interpretation bias, including neurophysiological indices, participants will be randomized to complete an online one-week daily CBM-I or sham training control condition training schedule. Following the one week training, individuals will return to the lab to complete further multi-faceted measures of interpretation bias and social anxiety symptoms. One week after this (i.e. 2 weeks post-basline), participants will complete a final set of symptom and bias measures online.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 22, 2023
CompletedFirst Posted
Study publicly available on registry
April 4, 2023
CompletedStudy Start
First participant enrolled
May 16, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2024
CompletedJune 25, 2024
June 1, 2024
1 year
March 22, 2023
June 24, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from baseline to follow-up (2 weeks post-baseline) in score on the Liebowitz Social Anxiety Scale, Self-Report (LSAS-SR)
A 24-item self-report scale assessing social anxiety symptoms over the past 7 days (Consbruch, Stangier \& Heidenreich, 2016; Liebowitz, 1987). Possible scores range from 0 (minimum) to 144 (maximum), with higher scores reflecting higher levels of social anxiety (i.e. worse outcomes). The primary outcome measure is change in score on the LSAS-SR from baseline to follow-up.
Baseline, Follow-up (2 weeks post-baseline)
Secondary Outcomes (10)
Liebowitz Social Anxiety Scale, Self-Report (LSAS-SR)
Post-training (1 week post-baseline)
Social Phobia and Anxiety Inventory, German version (SPAI-G)
Screening, Baseline, Post-training (1 week post-baseline), Follow-up (2 weeks post-baseline)
Depression, Anxiety, and Stress Scale-21 (DASS)
Baseline, Post-training (1 week post-baseline), Follow-up (2 weeks post-baseline)
Brief Fear of Negative Evaluation Scale (BFNE)
Baseline, Post-training (1 week post-baseline), Follow-up (2 weeks post-baseline)
Encoding Recognition Task (ERT)
Baseline, After last intervention session (~6 days post-baseline), Post-training (1 week post-baseline), Follow-up (2 weeks post-baseline)
- +5 more secondary outcomes
Other Outcomes (4)
Expectancy Questionnaire (EQ)
Baseline
Feedback Questionnaire
Follow-up (2 weeks post-baseline)
Negative Effects Questionnaire (NEQ)
Follow-up (2 weeks post-baseline)
- +1 more other outcomes
Study Arms (2)
Cognitive Bias Modification for Interpretation (CBM-I)
EXPERIMENTALParticipants in this arm complete an initial introductory session of Cognitive Bias Modification for Interpretation (CBM-I) in the lab followed by 6 sessions scheduled to be completed over the subsequent week (1 per day). CBM-I will be administered via an online platform using an individual login account.
Sham Training Control Condition
SHAM COMPARATORParticipants in this arm complete an initial introductory session of the sham training control condition in the lab followed by 6 sessions scheduled to be completed over the subsequent week (1 per day). CBM-I will be administered via an online platform using an individual login account.
Interventions
The CBM-I intervention is based on the interpretation training paradigm developed by Mathews and Mackintosh (2000). It comprises a series of training scenarios describing different (mostly everyday) socially-relevant situations, structured so they start ambiguously but always have a positive ending. The positive ending is presented as word fragment, which participants are instructure to complete. In about 25% of trials, participants are further requested to respond to comprehension questions about the scenario presented. Each CBM-I session comprises 45 trials presented in 5 blocks of 9 scenarios.
The sham training is in an identical format to the CBM-I training, except that the scenarios are all entirely neutral, with no reference to social situations and no emotional ambiguity.
Eligibility Criteria
You may qualify if:
- Provides informed consent
- Sufficient German language skills to complete the experimental tasks and questionnaires
- Aged between 18 and 65 years
- Scoring ≥ 52 on the SPAI-G (Turner et al., 1989; Fydrich, 2016), indicating elevated levels of social anxiety
- Lives within reasonable travelling distance of the research centre
You may not qualify if:
- Current psychotherapeutic treatment or psychotherapeutic treatment completed within the last 6 months prior to study enrolment.
- Current substance misuse or dependency (apart from Nicotine)
- Acute suicidality or self-harm
- Symptoms of a psychotic or bipolar disorder
- Presence of a somatic condition that could systematically affect cortisol levels (in particular: Pregnancy and lactation, adrenal dysfunction, thyroid dysfunction, pituitary dysfunction)
- Presence of a somatic condition that could systematically affect brain physiology (current or anamnestic neurological disorders, in particular: anamnestic traumatic brain injury, epilepsy, multiple sclerosis, brain tumors)
- Presence of a somatic condition that could systematically affect peripheral physiological measures (in particular: cardiovascular diseases (e.g., cardiac arrhythmias, circulatory diseases \[e.g., hypertension\]))
- Sensitivity or alteration of skin surface providing contraindication for EEG or periphysiological measures (in particular: baldness, dreadlocks, open wounds on the head or facial surface, skin conditions that cause particular sensitivity to gels and creams)
- Intake of psychotropic medication that cannot be interrupted during study duration or change in psychotropic medication within the 8 weeks before starting the study (except: antidepressants in unaltered dosage)
- Left handedness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ruhr University of Bochumlead
- Utrecht Universitycollaborator
- University of Osnabrueckcollaborator
Study Sites (1)
Mental Health Research and Treatment Center, Ruhr University of Bochum
Bochum, 44787, Germany
Study Officials
- PRINCIPAL INVESTIGATOR
Marcella L Woud, PhD
Ruhr University of Bochum
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- Participants are blind as to whether they have been allocated to the active training condition or sham training condition.
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Junior Professor
Study Record Dates
First Submitted
March 22, 2023
First Posted
April 4, 2023
Study Start
May 16, 2023
Primary Completion
May 31, 2024
Study Completion
May 31, 2024
Last Updated
June 25, 2024
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
- Time Frame
- Supporting information will be made available on publication via a suitable repository such as the Open Science Framework, and will be made available to reviewers at the time of submission (or publically with a pre-print version of the manuscript).
Anonymised data will be made available on publication via a suitable repository such as the Open Science Framework, and will be made available to reviewers at the time of submission (or publically with a pre-print version of the manuscript). Data made available will be the research data reported in the publication, withthe exception of any data that could compromise participant anonymity.